Literature DB >> 10853022

Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.

M Kondo1, H Nagano, M Sakon, H Yamamoto, O Morimoto, I Arai, A Miyamoto, H Eguchi, K Dono, S Nakamori, K Umeshita, K Wakasa, Y Ohmoto, M Monden.   

Abstract

Interferon-alpha (IFNalpha) plays a crucial role in the antiproliferation and immunoregulatory activity through the specific cell surface receptor, interferon-alpha/beta receptor (IFNalpha/betaR). We examined the immunohistochemical expression of IFNalpha/betaR in 91 hepatocellular carcinoma (HCC), HCV-related chronic hepatitis (n=38) and cirrhosis (n=53), dysplastic nodules (n=5), and normal liver (n=9). The level of IFNalpha/betaR increased in chronic hepatitis and cirrhosis compared with normal liver. All the dysplastic nodules showed moderate or high expression. In HCCs, 26% (24/91) of patients showed high IFNalpha/betaR expression while the remaining 38% (35/91) showed moderate, and 35% (32/91) no or faint expression. Clinicopathological survey demonstrated a significant correlation between IFNalpha/betaR expression and differentiation of carcinoma (P=0.0008) although there was no correlation between IFNalpha/betaR expression in HCC and survival or disease-free survival. Thus, IFNalpha/betaR was expressed not only in chronic hepatitis or liver cirrhosis but in HCC and its expression was significantly correlated with tissue differentiation of carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853022

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.

Authors:  Yasunari Hiramine; Hirofumi Uto; Yasushi Imamura; Kazuaki Tabu; Yoshirou Baba; Takuya Hiwaki; Yukihiko Sho; Kenji Tahara; Hirofumi Higashi; Tutomu Tamai; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

2.  Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon.

Authors:  Tomofumi Miura; Nobuaki Suzuki; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Hiroyuki Usuda; Iwao Emura; Toru Takahashi
Journal:  World J Hepatol       Date:  2010-11-27

3.  Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells.

Authors:  Y Tomimaru; H Eguchi; H Wada; T Noda; M Murakami; S Kobayashi; S Marubashi; Y Takeda; M Tanemura; K Umeshita; Y Doki; M Mori; H Nagano
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

4.  Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.

Authors:  Tameyoshi Yamamoto; Hiroaki Nagano; Yasuharu Imai; Kazuto Fukuda; Hitoshi Matsumoto; Motoi Kondo; Hideo Ota; Masato Nakamura; Hiroshi Wada; Takehiro Noda; Bazarragchaa Damdinsuren; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Kenichi Wakasa; Morito Monden
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

5.  A case of hepatocellular carcinoma with portal vein tumor thrombosis successfully treated by a combination of intra-arterial infusion 5-fluorouracil, cisplatin, and systemic interferon-α therapies.

Authors:  Tsutomu Kobayashi; Hideki Suzuki; Norio Kubo; Akira Watanabe; Shigeru Sasaki; Wataru Wada; Kenichiro Araki; Tatsuo Shimura; Hiroyuki Kuwano
Journal:  Int Surg       Date:  2012 Jul-Sep

6.  Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.

Authors:  Hiroshi Wada; Hiroaki Nagano; Takehiro Noda; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Masato Sakon; Kenichi Wakasa; Morito Monden
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 6.772

7.  The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.

Authors:  Satoru Hagiwara; Masatoshi Kudo; Kazuomi Ueshima; Hobyung Chung; Mami Yamaguchi; Masahiro Takita; Seiji Haji; Masatomo Kimura; Tokuzo Arao; Kazuto Nishio; Ah-Mee Park; Hiroshi Munakata
Journal:  J Gastroenterol       Date:  2010-08-04       Impact factor: 6.772

Review 8.  Tumor Restrictions to Oncolytic Virus.

Authors:  Markus Vähä-Koskela; Ari Hinkkanen
Journal:  Biomedicines       Date:  2014-04-17

9.  Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.

Authors:  H Ota; H Nagano; M Sakon; H Eguchi; M Kondo; T Yamamoto; M Nakamura; B Damdinsuren; H Wada; S Marubashi; A Miyamoto; K Dono; K Umeshita; S Nakamori; K Wakasa; M Monden
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

10.  Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.

Authors:  S Hagiwara; M Kudo; T Nakatani; Y Sakaguchi; M Nagashima; N Fukuta; M Kimura; S Hayakawa; H Munakata
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.